M
Emeran A. Mayer, MD
Director, UCLA G. Oppenheimer Center for Neurobiology of Stress and Resilience; Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at UCLA
Emeran Mayer is the director of the G Oppenheimer Center for the Neurobiology of Stress and Resilience (CNSR) at UCLA and co-director of the P30 funded CURE Digestive Diseases Research Center at UCLA. The CNSR is a NIH-funded, interdisciplinary and translational research center focused on brain gut microbiome interactions in 4 areas: Functional GI Disorders, Inflammatory Bowel Disorders, Ingestive Behavior/Eating Disorders, Chronic Visceral Pain Disorders. Within the CNSR, he has been the PI of a P50 SCOR grant from ORWH/NIDDK on sex-related differences in brain gut interactions with an emphasis on the effects of early adverse life effects on adult stress responsiveness and related brain circuits for the past 15 years. This grant has been successfully renewed over a total of three 5 year funding cycles under hisleadership. He is also the Co-PI of a UO1 grant focused on studying mechanisms of chronic pelvic pain (MAPP), now in its third 5 year funding cycle, and he leads the neuroimaging efforts within the consortium. Under his leadership, CNSR investigators have done pioneering work in applying psychophysiological and advanced brain imaging techniques to study the response of the brain to visceral stimuli in rodent models and human subjects with persistent visceral pain disorders, including IBS, IBD, IC/PBS and vulvodynia, to identify sex related differences in these brain responses, and to evaluate the effectiveness of pharmacologic and mind-based (including cognitive behavioral therapy) therapeutic approaches to some of these disorders. During the last 5 years, they have expanded their research efforts into the role of the gut microbiome in bidirectional brain gut interactions. They have pursued studies looking at the effect of altered autonomic nervous system output to the gut in altering gut microbial composition and function, and have been testing the hypothesis that gut microbial metabolites and inflammatory mediators in vulnerable patients can lead to neuroplastic changes in the central nervous system manifesting in persistent visceral hypersensitivity, cognitive decline and symptoms of autism spectrum disorders.
Publications:
http://www.ncbi.nlm.nih.gov/sites/myncbi/emeran.mayer.1/bibliograpahy/40552943/public